Michael Forbes, CEO of Adastra, said in his Preliminary press launch: “Damage reduction is actually a critically important and mainstream subject matter, and we're being with the forefront of drug regulations through the board.”“We'll Examine how the commercialization of this substance matches in with our business enterprise model at Adastra